Dr Ornstein on the Use of IO/TKI Doublets in Non-ccRCC - OncLive
Moshe Ornstein discusses IO/TKI doublet regimens in non-ccRCC, highlighting KEYNOTE-B61 trial (ORR 51%, median PFS 17.9 months) and cabozantinib/nivolumab trial (ORR 48%, median PFS 13 months). Both regimens supported by NCCN guidelines, emphasizing IO/TKI as standard care for non-ccRCC patients.
Related Clinical Trials
Highlighted Terms
Related News
Dr Ornstein on the Use of IO/TKI Doublets in Non-ccRCC - OncLive
Moshe Ornstein discusses IO/TKI doublet regimens in non-ccRCC, highlighting KEYNOTE-B61 trial (ORR 51%, median PFS 17.9 months) and cabozantinib/nivolumab trial (ORR 48%, median PFS 13 months). Both regimens supported by NCCN guidelines, emphasizing IO/TKI as standard care for non-ccRCC patients.